Scoop has an Ethical Paywall
Pacific Edge Undertakes $8m Share Placement
Pacific Edge Undertakes $8m Share Placement
Capital Investment To Assist The Push Through To Cashflow-Positive Position
Cancer diagnostics company Pacific Edge Limited (NZX:PEB) has undertaken an $8.0 million share placement to institutional and other select investors in New Zealand.
The placement was undertaken at no discount to market, with institutional and other select investors subscribing for new shares at $0.50 cents per share, the market price of Pacific Edge Limited shares traded on Tuesday 14 February 2017.
Pacific Edge is focused on building sales of its suite of innovative Cxbladder bladder cancer diagnostic tests and has been gaining traction in the USA market with a number of milestone achievements in the past year.
Pacific Edge Chairman Chris Gallaher commented: “The strong support we received for the share placement from institutional and other select investors in New Zealand has allowed us to cost efficiently and effectively strengthen our balance sheet as we continue to make good traction towards attaining a cashflow-positive position.”
ends
University of Auckland: Kids’ Screen Use Linked To Long-Term Deficits In Self-Control And Attention
University of Auckland: Research To Address Equity In STEM For Māori, Pacific And Female Students
Stats NZ: Economic Impacts On New Zealand From Conflict In The Middle East – Report
Advertising Standards Authority: ASA Annual Report 2025 - Platform-Neutral Regulation Keeps Pace With Digital Advertising
Science Media Centre: Lead Pipes Banned For New Plumbing – Expert Reaction
New Zealand Young Physicists Trust: Auckland To Host The ‘World Cup Of Physics’ In 2027; Search Begins For Student-Designed Tournament Logo
